New Roth IRA Calculator Subtracts Guesswork, Adds Peace of Mind

Business Wire, Nov 17, 1998

NEW YORK--(BUSINESS WIRE)--Nov. 17, 1998--The newest "best-in-class" power tool to hit the Internet - the Net Technologies, Inc. Roth IRA Calculator - debuts today at www.tucker-anthony.com, the Web site of Northeast regional brokerage firm Tucker Anthony Incorporated.

The first Web-based IRA conversion calculator to be classified as "high end" by Roth IRA expert Dr. Gobind Daryanani, the NTI Roth IRA Calculator offers more features, improved functionality and greater accuracy than any other equivalent tool in the marketplace.

"Overall, this is the best Web-based calculator currently available," said Dr. Daryanani, founder of the Roth IRA Conversion Consulting Service and author of the recent study, Market Analysis of Roth IRA Calculators. "The technology is robust and better than others on the Internet right now. Its ease-of-use enables any individual with the ability to turn on a computer to powerfully arm himself with the knowledge it takes to make the right retirement decisions. This is what retirement planning on the Internet is all about."

In Dr. Daryanani's comprehensive study of all currently available calculators, he notes many features that make this tool a standout. These include:

-- The ability to consider minimum required distributions (both term

certain and recalculation methods.)

-- The ability to not only provide information on eligibility for

the various IRA options, but also to determine the amount that

may be contributed in the phase-out income levels (a feature

deemed "best-in-class" by Dr. Daryanani).

-- The use of annualized pay-out during the distribution years to

compare the various IRA options. This model is considered more

realistic than the "lump-sum" distribution model used in many

other calculators, in which all monies are distributed in one

year.

-- The ability to generate comprehensive reports online that can be

readily printed and that explain results in-depth (currently, the

only Web-based calculator with this feature).

-- A convenient split-screen display that shows both inputs and

results, allowing the user to instantly see the effects of

different scenarios (this is particularly useful for brokers in

explaining these various scenarios to clients).

-- The ability to quickly construct extensive tables that can be

used to follow various steps in the calculations.

-- The graphic display of results highlighting only the essential

data for those who are just interested in the bottom line.

Tucker Anthony worked closely with Net Technologies in developing the Roth IRA Calculator. Al Yee, Executive Vice Presidegoal," said Yee. "And with the year-end deadline looming for converting to the four-year tax payment option, we are pleased that our site will be able to effectively facilogies. "With so many Web-based calculators out there, each spitting out different numbers, it's not surpris, easy to use and highly accurate calculator to help our customers make timely and important retirement decis The NTI Roth IRA Calculator is the first in a suite of Web-based financial planning tools developed by Net Technologies, Inc. The other four to be launched within the next few months will be "Planning for Retirement," "Living in Retie Internet solutions to help financial services companies gain a strategic advantage over their competitors.an 35 offices throughout the Eastern and Midwestern regions of the United States, the firm has been providincom

or

Padilla Speer Beardsley

Richard Franco/Alexis Thomas

TIVE/MULTIMEDIA/INTERNET PRODUCT

Today's News On The Net - Business Wire's full file on the Internet

anion Animal Health Agreement

Health/Medical Writers

THE WOODLANDS, Texas--(BUSINESS WIRE)--Nov. 17, 1998-- GeneMedicine Inc. (Nasdaq:GMED) announced today that it has entered into an agreement with Heska Corporation, Fort Collins, Colo. (Nasdaq:HSKA), under which Heska has the exclusive right to evaluate GeneMedicine's proprietary cationic lipid and polymer-based DNA formulation and delivery technologies for certain immunotherapeutic applications in companion animal health. Under the agreement, GeneMedicine will receive an option fee and, if Heska exercises its option to acquire an exclusive license, GeneMedicine will also receive license fees, milestone payments and royalties.

GeneMedicine's formulation and delivery technology is intended to treat disease through targeted delivery of plasmid based medicines to either produce therapeutic proteins or stimulate helpful immune responses. GeneMedicine technology is being evaluated for several applications including both local and systemic delivery of immune-modulating therapeutic gene products for the treatment of cancer and certain infectious diseases. These plasmid-based delivery technologies are non-replicating and non-immunogenic, thus allowing for repeated administration of the formulation with sustained efficiency. GeneMedicine is currently evaluating these platforms in human clinical trials both in Europe and the U.S. for the treatment of cancer.

"Heska continues to look for novel, safe and effective treatments for serious health conditions that affect companion animals," said Dr. Robert Grieve, Heska's chief scientific officer. "This agreement with GeneMedicine will provide Heska with access to exciting proprietary technology that may allow us to offer veterinarians a safe, non-toxic, and convenient method for treating companion animals suffering from cancer, in addition to treating infectious diseases through targeted activation of the pet's immune system."